CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.

Reducing the activity of a specific protein could provide significant relief for many heart failure patients.

Michael McKee is accused of making the journey from Illinois to Ohio and then shooting the two victims in their home on Dec. 30. He was arrested after surveillance footage showed his car at the scene before and after the murders. 

Postprocedural gradients can tell cardiologists a lot about a patient's long-term risk of structural valve deterioration.

The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment. 

Vapor 2000 and Vapor 3000 devices manufactured by Draegar were improperly cleaned after parts were soldered on, meaning toxic metals could mix with medical gases. Due to the high risk posed to patient health, this recall has earned the FDA’s most serious designation. 

Boston Scientific sent all known customers a letter on December 19, 2025 alerting them to an issue with certain AXIOS Stent and Electrocautery Enhanced Delivery Systems. During deployment, the stents may not expand. This can cause severe, potentially life-threatening injury to patients. All recalled stents must be removed from clinical settings immediately. 

The intra-annular, self-expanding Navitor valve gained FDA approval in 2023 for the treatment of high-risk heart patients with severe aortic stenosis. This analysis explores its early impact on patient care.